Physician profile
Patricia M Harkins
NPI 1063482248
$5,246.14
in general payments reported to CMS, 2019-2025
14 companies · $331 in 2025
The $331 reported for 2025 was more than what 80% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $235 · 2021: $3,076 · 2022: $498 · 2023: $411 · 2024: $379 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,910.00 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $678.74 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $540.55 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $347.70 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $210.26 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $120.38 | 2019-2024 | Relexxii |
| Collegium Pharmaceutical, INC. | $106.21 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $87.72 | 2019-2022 | |
| Shire North American Group INC | $69.24 | 2019 | |
| Adlon Therapeutics L.P. | $67.14 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $32.48 | 2024 | Daybue |
| Aprecia Pharmaceuticals, LLC | $29.85 | 2023 | Spritam |
| Alfasigma USA, INC. | $28.08 | 2020 | |
| Sunovion Pharmaceuticals INC. | $17.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Harkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.